Switching Maintenance Infliximab Therapy to Biosimilar-Infliximab does Not Lead to Significant Changes in Health-Related Quality of Life and Clinical Outcomes in Inflammatory Bowel Disease Patients
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.833
https://www.valueinhealthjournal.com/article/S1098-3015(17)31167-1/fulltext
Section Title :
Disease-Specific Studies
Section Order :
793
First Page :
A545
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31167-1&doi=10.1016/j.jval.2017.08.833